Parkinson's disease with and without Freezing of Gait, healthy controls.
Conditions
Interventions
1. Parkinson's disease patients with Freezing of Gait, Parkinson's disease patients without Freezing of Gait and healthy controls will be assessed with a set-shifting task in a behavioral setting and
2. Parkinson's disease patients with Freezing of Gait will be treated with Methylphenidate or placebo for three months with a dosage of 1 mg/kg/day. Methylphenidate or placebo will be randomly assigne
3. After three months the assessment of gait characteristics and set-shifting in a behavioral setting and during fMRI-EMG will be repeated in Parkinson's disease patients with Freezing of Gait.
Sponsors
University Medical Center Groningen
University of Groningen
Eligibility
Inclusion criteria
Inclusion criteria: Parkinson's disease according to the UK brain bank criteria.
Exclusion criteria
Exclusion criteria: 1. Presence of neurological central nervous system disorders other that idiopathic PD; 2. Surgical treatment for idiopathic PD, such as deep brain stimulation; 3. Dementia; 4. Other significant co-morbidity; 5. Contraindications to MRI scanning; 6. Contraindications to the use of Methylphenidate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First primary outcome: Performance of Parkinson's disease patients with Freezing of Gait on behavioral tasks compared to Parkinson's disease patients without Frezzing of Gait and healthy controls. Second primary outcome: Cerebral activation patterns during shifting between response sets in Parkinson's disease patients with Freezing of Gaot, relative to Parkinson's disease patients without Freezing of Gait and healthy controls. Third primary outcome: Change of performance on response shifting task and gait trajectory after administration of Methylphenidate in Parkinson's disease patients with Freezing of Gait, relative to placebo. Fourth primary outcome: Cerebral activation change after administration of Methylphenidate in Parkinson's disease patients with Freezing of Gait, relative to placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| First secondary outcome is the performance on the motor tasks of all groups, compared to the performance on the cognitive task and dual task, by comparing the number of correct responses. Second secondary outcome is the cerebral activation pattern during shifting between motor task compared to the cerebral activation patterns during shifting between cognitive tasks and during dual tasks in all groups. | — |
Contacts
Public ContactJanneke Koerts
Hanzeplein 1
Outcome results
None listed